JP2014518198A - Ｉｌ−２１のエピトープおよびｉｌ−２１リガンド - Google Patents

Ｉｌ−２１のエピトープおよびｉｌ−２１リガンド Download PDF

Info

Publication number
JP2014518198A
JP2014518198A JP2014513193A JP2014513193A JP2014518198A JP 2014518198 A JP2014518198 A JP 2014518198A JP 2014513193 A JP2014513193 A JP 2014513193A JP 2014513193 A JP2014513193 A JP 2014513193A JP 2014518198 A JP2014518198 A JP 2014518198A
Authority
JP
Japan
Prior art keywords
antibody
seq
epitope
glu
mab14
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014513193A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518198A5 (cg-RX-API-DMAC10.html
Inventor
アンデルス・スヴェンソン
メッテ・ダール・アンデルセン
イェンス・ブラインホルト
シャロテ・ヴィベア
ハネ・ベネディクト・ラスムッセン
ビーリト・オールスン・クローウ
Original Assignee
ノヴォ ノルディスク アー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノヴォ ノルディスク アー／エス filed Critical ノヴォ ノルディスク アー／エス
Publication of JP2014518198A publication Critical patent/JP2014518198A/ja
Publication of JP2014518198A5 publication Critical patent/JP2014518198A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014513193A 2011-05-31 2012-05-31 Ｉｌ−２１のエピトープおよびｉｌ−２１リガンド Withdrawn JP2014518198A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11168327.2 2011-05-31
EP11168327 2011-05-31
US201161492990P 2011-06-03 2011-06-03
US61/492,990 2011-06-03
PCT/EP2012/060248 WO2012164021A1 (en) 2011-05-31 2012-05-31 Il-21 epitope and il-21 ligands

Publications (2)

Publication Number Publication Date
JP2014518198A true JP2014518198A (ja) 2014-07-28
JP2014518198A5 JP2014518198A5 (cg-RX-API-DMAC10.html) 2015-07-16

Family

ID=47258396

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014513193A Withdrawn JP2014518198A (ja) 2011-05-31 2012-05-31 Ｉｌ−２１のエピトープおよびｉｌ−２１リガンド

Country Status (5)

Country Link
US (1) US20140170153A1 (cg-RX-API-DMAC10.html)
EP (1) EP2714198A1 (cg-RX-API-DMAC10.html)
JP (1) JP2014518198A (cg-RX-API-DMAC10.html)
CN (1) CN103702721A (cg-RX-API-DMAC10.html)
WO (1) WO2012164021A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014205501A1 (en) * 2013-06-27 2014-12-31 Monash University Il-21 binding proteins and uses thereof
AR099625A1 (es) 2014-03-21 2016-08-03 Lilly Co Eli Anticuerpos de il-21
JP6672175B2 (ja) * 2014-05-07 2020-03-25 ノヴォ ノルディスク アー／エス Ｇｌｐ−１及び抗ｉｌ−２１を使用した１型糖尿病の治療
PT3139948T (pt) * 2014-05-07 2020-05-22 Novo Nordisk As Tratamento de diabetes usando glp-1 e anti-il-21
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
CN107249633A (zh) * 2014-12-19 2017-10-13 迈博太科公司 用于抑制il‑21介导的人细胞活化的组合物、试剂盒和方法
KR20240115352A (ko) * 2017-12-06 2024-07-25 팬디온 오퍼레이션스, 인코포레이티드 Il-2 뮤테인 및 그 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010055366A2 (en) * 2007-12-07 2010-05-20 Zymogenetics, Inc. Anti-human il-21 monoclonal antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
US20070122413A1 (en) * 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
WO2009047360A1 (en) * 2007-10-11 2009-04-16 Novo Nordisk A/S Il-21 antibodies
WO2009132821A1 (en) * 2008-04-28 2009-11-05 Giuliani International Limited Interleukin (il-21) binding proteins and methods of making and using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010055366A2 (en) * 2007-12-07 2010-05-20 Zymogenetics, Inc. Anti-human il-21 monoclonal antibodies

Also Published As

Publication number Publication date
US20140170153A1 (en) 2014-06-19
EP2714198A1 (en) 2014-04-09
WO2012164021A1 (en) 2012-12-06
CN103702721A (zh) 2014-04-02

Similar Documents

Publication Publication Date Title
JP7610541B2 (ja) 結合タンパク質及びその使用方法
CN108367075B (zh) 4-1bb结合蛋白及其用途
JP6280526B2 (ja) Ｉｌ−４および／またはｉｌ−１３に結合する抗体およびそれらの使用
KR101625961B1 (ko) 인터루킨-13 결합 단백질
US11136366B2 (en) Methods of treating immune related disorders using antibody-cytokine engrafted compositions
JP2014506259A (ja) Ｉｌ−２１リガンド
US20120230911A1 (en) Tnf-alpha binding proteins
CN110072891A (zh) 抗人cd73抗体
TW201031421A (en) IL-1 binding proteins
US10583191B2 (en) Antibodies against LIF and uses thereof
JP2013005805A (ja) 改変された抗ｉｌ−１３抗体、組成物、方法、及び使用
CN114751982B (zh) 抗人ngf抗体及其制备方法和用途
US20250122254A1 (en) Recombinant Fusion Proteins Comprising Interleukin- 18-Binding Protein and Antigen Binding Fragment to Serum Albumin, and Compositions and Uses Thereof
US20140170153A1 (en) Il-21 epitope and il-21 ligands
TW201134489A (en) Basigin binding proteins
JP7709757B2 (ja) 猫の顆粒球コロニー刺激因子及び血清アルブミン抗原結合断片を含む組み換えタンパク質、並びにその用途
WO2014006230A1 (en) Il-20 epitopes and il-20 ligands
HK1180980A (en) Il-17a antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160509

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20160608